

ASX Announcement

24 August 2026

FY 26 Annual Results & Investor Webinar

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company, will release its FY2026 annual results on Tuesday, 25 August 2026.

Following the release of the FY2026 annual results, the Company will host an investor webinar at 10am (AEST) on Wednesday, 26 August 2026 where Chief Executive Officer, Maria Halasz and Head of Finance, Ange Wang will present the results and address investor questions.

To register for the session and submit your questions in advance, please visit this link:

https://vistra.zoom.us/webinar/register/WN_3vlf01gXSiKN34zYbBoIEA

– END –

Announcement authorised by the Chief Executive Officer

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz

Chief Executive Officer

maria.halasz@geneticsignatures.com

Ange Wang

Head of Finance

ange.wang@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary 3base® platform technology provides high-volume hospital and pathology laboratories with the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are hospitals and pathology laboratories undertaking infectious disease screening.